The results of a phase I/II study reveal that the selective aurora kinase A inhibitor alisertib might be an effective treatment of a range of solid tumours. Following oral administration of alisertib, partial responses to therapy were detected in some patients with breast (18%), small-cell lung (21%) or non-small-cell lung (4%), gastroesophageal (9%), or head and neck cancers (9%). In total, 43% of patients reported serious adverse events. Further testing, in phase III clinical trials, is required to establish the efficacy of alisertib.
References
Melichar, B. et al. Safety and activity of alisertib, an investigational aurora kinase Ainhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol. 10.1016/S1470-2045(15)70051-3
Rights and permissions
About this article
Cite this article
Alisertib tested in patients with solid tumours. Nat Rev Clin Oncol 12, 312 (2015). https://doi.org/10.1038/nrclinonc.2015.56
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.56
